Ask the Experts
Do you have a question you would like our experts to answer?
A new video from our partners at OncLive discusses how Dr. Fakhri selects treatment regimens for her patients. Currently, physicians use 2 factors to pick a regimen for a patient—transplant eligibility versus ineligibility and the genomics of their disease,...read more
Watch this video CME from our partners at Plexus Communications on the management of patients with multiple myeloma. Ola Landgren, MD, PhD, co-chair of the World Myeloma Forum, discusses the diagnosis, staging, risk stratification, cytogenetics, and treatment...read more
Dr. Yasar Shad, a Hematology/Oncology fellow from Columbia MO, asked where he might find additional reading/references on the cytogenetics and molecular genetics of multiple myeloma. We just wrote this very recent update. It includes current and future technologies. I...read more
There is growing interest in Minimal Residual Disease (MRD) testing and assessment in multiple myeloma (MM). In part, this interest is related to the novel agents and improved response rates seen with their increased usage. This has lead to the development of reliable...read more
Voorhees, who specializes in hematology and medical oncology at Levine Cancer Institute, Carolinas HealthCare System and UNC Chapel Hill, discussed treatments for both newly diagnosed and relapsed patients with multiple myeloma during the 2017OncLive® State of the...read more
Join Our Community
By joining the Myeloma360 community, you will receive regular updates with news, information, insights and expert opinions.
Of course, you can opt out at any time.